Immutep (ASX:IMM) Share Price and News

Market Cap (19-Sep) $82,528,400 (530th)	Close (30-Jun) $0.315 0 (0%)	Volume (30-Jun) 2,012,212	Shortsold (26-May) 47,225,403 (3.20%) (112th)
52w High $0.470	52w Low $0.028	P/E 7.20	EPS -0.05

	Subject
	IMM IMM Article: Immutep raises $100m and signs with Merck on ‘blockbuster’ drug
	1 (current) 2 3
	IMM IMM Article: Biotech Immutep seeks $102 million, taps three brokers
	IMM IMM Article: Perennial fundie’s top small-cap healthcare picks
	IMM IMM Ann: Application for quotation of securities - IMM
	IMM IMM Ann: US patent granted for Efti with PD-1 pathway inhibitor
	IMM IMM Ann: Immutep completes underwritten retail entitlement offer
	IMM IMM Ann: Immutep granted US patent for IMP761 agonist LAG-3 antibody
	IMM IMM Ann: Change in substantial holding from IFL
	IMM IMM Ann: Change in substantial holding
	IMM IMM Ann: Change in substantial holding
	IMM IMM Ann: Becoming a substantial holder
	IMM IMM Ann: Cleansing Notice
	IMM IMM Ann: Application for quotation of securities - IMM
	IMM IMM Ann: Immutep letter to ineligible shareholders
	IMM IMM Ann: Immutep retail entitlement offer booklet
	IMM IMM Ann: Positive final data in 2nd line head and neck cancer at ASCO
	IMM IMM Article: Fundies pile into Immutep $80m raise
	IMM IMM Ann: Immutep completes institutional pro-rata offer & placement
	IMM IMM Ann: Change in substantial holding
	IMM IMM Article: Immutep in $80m raise; Bells, Jefferies and Wilsons on ticket
	IMM IMM Ann: Cleansing Notice
	IMM IMM Ann: Proposed issue of securities - IMM
	IMM IMM Ann: Immutep Capital Raising Presentation
	IMM IMM Ann: A$80 million fully underwritten equity raising
	IMM IMM Ann: Trading Halt
	IMM IMM Ann: Charles River Laboratories to run IMP761 Toxicology Study
	IMM IMM Ann: Publication of Abstracts for ASCO 2023 Annual Meeting
	IMM IMM Ann: 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
	IMM IMM Ann: Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
	IMM IMM Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC
	IMM IMM Ann: FDA supportive of Efti registrational trial in lung cancer
	IMM IMM Ann: Change of Director's Interest Notice - R Howard
	IMM IMM Ann: Approval to start Efti & Bavencio trial in urothelial cancer
	IMM IMM Ann: Immutep Quarterly Activities Report and Appendix 4C
	IMM IMM Ann: Immutep to announce new TACTI-002 data at ASCO 2023
	IMM IMM Ann: Immutep appoints Dr Florian Vogl as Chief Medical Officer
	IMM IMM Ann: Response to ASX Aware Query
	IMM IMM Ann: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
	IMM IMM Ann: Notification of cessation of securities - IMM
	IMM IMM Article: ASX to edge higher; Newmont increases bid for Newcrest
	IMM IMM Ann: Appendix 3Z - Lucy Turnbull
	IMM IMM Ann: Appendix 3X - Lis Boyce
	IMM IMM Ann: Immutep Announces Changes to the Board
	IMM IMM Ann: Positive Final Data in 2nd Line Metastatic NSCLC Patients
	IMM IMM Ann: Change in substantial holding
	IMM IMM Ann: Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
	IMM IMM Ann: Abstract accepted for ESMO's European Lung Cancer Congress
	IMM IMM Ann: Initiation of Ph 2/3 Trial for Metastatic Breast Cancer
	IMM IMM Ann: Half Yearly Report and Accounts
	IMM IMM Ann: Enrolment Target Reached for INSIGHT-003 Trial in NSCLC

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

End of Day Prices

Date	Close	Volume	Change
18-Sep	$0.25	826,810	+0.02 (8.70%)
12-Sep	$0.23	1,043,977	-0.01 (4.17%)
11-Sep	$0.24	1,234,740	+0.01 (2.13%)
05-Sep	$0.24	1,709,994	-0.01 (4.08%)
04-Sep	$0.25	1,530,936	+0.01 (2.08%)
03-Sep	$0.24	1,360,610	+0.01 (2.13%)
29-Aug	$0.24	7,230,221	-0.01 (4.08%)
28-Aug	$0.25	449,870	-0.01 (3.92%)
22-Aug	$0.26	2,536,585	+0.01 (4.08%)
21-Aug	$0.25	2,037,806	-0.02 (7.55%)
15-Aug	$0.27	2,774,453	+0.01 (3.92%)
14-Aug	$0.26	7,751,917	-0.03 (8.93%)
07-Aug	$0.28	4,032,467	+0.01 (3.70%)
31-Jul	$0.27	690,429	+0.01 (1.89%)
30-Jul	$0.27	1,498,068	-0.01 (1.85%)
8 up, 7 down, and 0 flat days

High $0.32	Low $0.30	Trades 243	Turnover $627,825	Volume 2,012,212
30 June 2023 at 4:10pm

High $0.32	Low $0.30	Trades 243	Turnover $627,825	Volume 2,012,212
30 June 2023 at 4:10pm

Immutep Health Care
Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

$0.315 0.010 (3.28%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices

IMM Immutep Health Care Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

$0.315 0.010 (3.28%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Immutep Health Care
Cancer Pharmaceuticals